This site requires the latest version of Macromedia Flash Player.

Cash Balance: $754 MM (as of 06/30/09)
Dollars invested in R&D since inception: $2,015,896,000
Drugs in pipeline: 9 (plus 1 marketed)
Institutional Ownership: 92.2% (as of 2/08/08)
Number of patients expected to enroll in telaprevir Phase 3 program: 2,200
2008 Revenue: $175 MM
2008 R&D expense: $516 MM

2010 Priorities:

•		Complete Phase 3 registration program for telaprevir
•		Complete enrollment for VX-770 Phase 3 registration program
•		Submit New Drug Application for telaprevir
•		Initiate combination trial of telaprevir and VX-222
•		Initiate combination trial of VX-770 and VX-809
•		Initiate proof-of-concept trials for VX-765 and VX-509

2009 Achievements:

✓		Complete enrollment in Phase 3 program for telaprevir in treatment-naïve and treatment-failure patients
✓		Initiate registration program for VX-770 in cystic fibrosis
✓		Initiate Phase 2 development for VX-809